Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 17,131
- Estimated value
- $44,026
- Report date
- 29 May 2026
- Price
- $2.57
- Ownership
- Direct
David Young
Insider Reports History
- Reporting-owner location
- Columbia, MD
- Latest reporting-owner signature
- /s/ David Young by John J. Wolfel, as Attorney-in-Fact
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for David Young
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- $43,015
- Report date
- 01 Jan 2026
- Price
- $1.71
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 1,242
- Estimated value
- $3,129
- Report date
- 29 May 2026
- Price
- $2.52
- Ownership
- By Young-Plaisance Revocable Trust
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 742
- Estimated value
- $1,869
- Report date
- 29 May 2026
- Price
- $2.52
- Ownership
- By CorLyst, LLC
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 432
- Estimated value
- $1,088
- Report date
- 29 May 2026
- Price
- $2.52
- Ownership
- By Family Entities
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 333,000
- Estimated value
- Report date
- 01 Oct 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Pres. Research & Development, Director
Processa Pharmaceuticals, Inc.
- Security class
- Warrants
- Shares / value
- 62,250
- Estimated value
- Report date
- 29 Jan 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by David Young
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 29 May 2026
- Transactions
- 1
- Transaction value
- +$4,590
- Accepted by SEC
- 01 Jun 2026, 17:01
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 15 May 2026
- Transactions
- 1
- Transaction value
- +$4,589
- Accepted by SEC
- 19 May 2026, 18:04
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 30 Apr 2026
- Transactions
- 1
- Transaction value
- +$4,589
- Accepted by SEC
- 01 May 2026, 16:39
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 15 Apr 2026
- Transactions
- 1
- Transaction value
- +$4,589
- Accepted by SEC
- 17 Apr 2026, 16:55
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 31 Mar 2026
- Transactions
- 1
- Transaction value
- +$4,588
- Accepted by SEC
- 01 Apr 2026, 17:20
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Jan 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Feb 2026, 17:09
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Oct 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Oct 2025, 16:25
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4/A
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 24 Jul 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Sep 2025, 16:24
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Apr 2025
- Transactions
- 2
- Transaction value
- -$2,202
- Accepted by SEC
- 11 Apr 2025, 17:16
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4/A
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 27 Jan 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Feb 2025, 17:57
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 05 Apr 2024
- Transactions
- 8
- Transaction value
- -$1,927
- Accepted by SEC
- 02 Aug 2024, 17:09
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 07 Feb 2024
- Transactions
- 1
- Transaction value
- +$51,526
- Accepted by SEC
- 08 Feb 2024, 16:30
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 06 Feb 2024
- Transactions
- 1
- Transaction value
- +$50,504
- Accepted by SEC
- 07 Feb 2024, 16:22
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Jan 2024
- Transactions
- 3
- Transaction value
- -$1,445
- Accepted by SEC
- 12 Apr 2024, 17:01
- Role
- Pres. Research & Development, Director
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 12 Oct 2023
- Transactions
- 1
- Transaction value
- +$45,030
- Accepted by SEC
- 12 Oct 2023, 17:54
- Role
- Pres. Research & Development, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 10 Oct 2023
- Transactions
- 1
- Transaction value
- +$34,080
- Accepted by SEC
- 10 Oct 2023, 17:03
- Role
- Pres. Research & Development, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 12 Jun 2023
- Transactions
- 1
- Transaction value
- +$32,000
- Accepted by SEC
- 12 Jun 2023, 16:31
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 14 Apr 2023
- Transactions
- 1
- Transaction value
- +$10,998
- Accepted by SEC
- 14 Apr 2023, 18:16
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 11 Apr 2023
- Transactions
- 3
- Transaction value
- +$29,000
- Accepted by SEC
- 13 Apr 2023, 16:51
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 09 Feb 2023
- Transactions
- 1
- Transaction value
- +$15,000
- Accepted by SEC
- 10 Feb 2023, 16:04
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 31 Dec 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2023, 16:39
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 30 Sep 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Oct 2022, 16:48
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 16 Aug 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Aug 2022, 16:30
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 05 Aug 2022
- Transactions
- 2
- Transaction value
- -$8,023
- Accepted by SEC
- 09 Aug 2022, 16:26
- Role
- President & CEO, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 30 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2022, 17:33
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Apr 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Apr 2022, 18:00
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4/A
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2022, 16:31
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 01 Nov 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Apr 2022, 17:45
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4/A
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 30 Sep 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2022, 14:57
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 05 Aug 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Aug 2021, 16:33
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 08 Jul 2021
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 09 Jul 2021, 16:33
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 23 Jun 2021
- Transactions
- 1
- Transaction value
- +$76,716
- Accepted by SEC
- 23 Jun 2021, 17:12
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
PCSA
Processa Pharmaceuticals, Inc.
- Report period
- 08 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2021, 17:04
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details